Cabozantinib for Advanced ACC: 1MO An Open-label
Adrenocortical carcinoma (ACC) is an uncommon kind of endocrine cancer with few available...
Read More
Hematology/Oncology
MM Patients: Single-agent anti-PD-1 or Combined Ipilimumab
An uncommon form of melanoma with a dismal prognosis, mucosal melanoma (MM) has a unique biology....
Read More
Pimitespib in Advanced GIST Patients (CHAPTER-GIST-301)
It is not good news when gastrointestinal stromal tumors (GIST) are progressed and are resistant...
Read More
Decipher GC Validation in Patients Receiving SRT Without Hormone Therapy after Radical Prostatectomy
The Decipher genomic classifier (GC) has demonstrated the ability to predict prostate cancer...
Read More
WGTA Enhances Precision Cancer Treatment Options
Precision genomic medicine is now being delivered to cancer clinics thanks to recent developments....
Read More
Pembrolizumab in MSI-H or Mismatch Repair Deficient Cancers
In phase II multicohort KEYNOTE-158 research, pembrolizumab showed persistent anticancer efficacy...
Read More
As A Lymphodepletion Therapy Prior to Tisagenlecleucel, Bendamustine Is Safe and Effective
B-cell non-Hodgkin lymphomas that have relapsed or become resistant to treatment are often treated...
Read More
Acetaminophen and Immunotherapy Effectiveness in Cancer Patients
Use of acetaminophen (APAP) has been linked to weakened immunological responses to vaccinations....
Read More
Immunotherapy for Non-Small-Cell Lung Cancer with Unresectable Stage III
Concurrent chemoradiotherapy (CCRT) and adjuvant durvalumab are the recommended treatments for...
Read More
Docetaxel-Related Adverse Events Depend On Castration Status?
Neutropenia and febrile neutropenia (FN), which are docetaxel-related adverse effects (AEs), can...
Read More
In Patients with Castration-Resistant Prostate Cancer, Elevated Serum CEA Is Associated with Liver Metastasis and Distinctive Circulating Tumor DNA Alterations
Castration-resistant prostate cancer (CRPC) “treatment emergent” types, such as...
Read More
ASTRO Offers Guidance on RT for IDH-Mutant Diffuse Grade 2, 3 Glioma
MONDAY, Sept. 19, 2022 (HealthDay News) — In a clinical practice guideline issued by the...
Read More
Photon-Counting Detector CT Helps ID Multiple Myeloma Lesions
MONDAY, Sept. 19, 2022 (HealthDay News) — Photon-counting detector (PCD) computed tomography...
Read More
Squamous Cell Carcinoma of the Lung: Treatment Considerations
The researchers found that squamous cell carcinoma (SCC) of the lung is a subtype of non-small...
Read More
inDEPTH: HIV & Prostate Cancer Prevention
inDEPTH examines topics with perspectives from your colleagues through multiple lenses to...
Read More
How Is Cervical Cancer Advancing to Stage IV in The USA?
Cervical cancer, stage IVA-B (remote stage) according to the International Federation of...
Read More
Characterizing ERBB2 (HER2) Mutations and Comparing Outcomes: Trastuzumab and NSCLC
According to researchers, 3 to 5% of patients with mNSCLC have ERBB2 (HER2) mutations. However, no...
Read More
Osimertinib Resistance in Hispanics with Non-Small Cell Lung Cancer Mutant EGFR
Patients with advanced non-small cell lung cancer are eligible for first-line treatment with...
Read More
Treatment of Non-Small Cell Lung Cancer with Pembrolizumab Results in Skin and Pulmonary Sarcoidosis
As a result of the researchers’ work on developing immunotherapy drugs known as immune...
Read More
Patients with Lung Cancer May Encounter Delays in Care Due to The COVID-19 Pandemic
Lung cancer patients may have treatment delays due to the 2019 coronavirus disease (COVID-19)...
Read More